Denali Therapeutics Inc. DNLI
Set alert
At close · Oct 30
After hours · Oct 30, 4:59 PM ET
- YTD
- +14.72%
- 1 year
- +15.63%
- Open
- 19.25
- Prev close
- 19.32
- Mkt cap
- 3.03B
- Vol
- 1.31M
- Avg vol
- 1.57M
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.64
- High
- 19.63
- Forward P/E
- -7.84
- Beta
- 1.02
- Short ratio
- 7.76
- Inst. own
- 101.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.76
- 200-d avg
- 21.23
- 1y target
- 35.50
News
1 day ago globenewswire.com
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best…
2 weeks ago benzinga.com
Denali Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
-
2 months ago benzinga.com
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
-
2 months ago benzinga.com
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
-
2 months ago benzinga.com
Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of…
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
-
3 months ago benzinga.com
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35
Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.
-
3 months ago benzinga.com
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.
-
4 months ago benzinga.com
Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M
Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million.…
-
5 months ago benzinga.com
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.
-
5 months ago benzinga.com
Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary Endpoints
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue…
-
5 months ago benzinga.com
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.
-
5 months ago benzinga.com
BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.
-
5 months ago benzinga.com
Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.71) by 2.82 percent. This is a 11.54 percent increase over losses of…
5 months ago benzinga.com
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.
6 months ago benzinga.com
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
-
6 months ago benzinga.com
Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.
6 months ago benzinga.com
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.
-
6 months ago benzinga.com
Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with…
-
7 months ago benzinga.com
Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa
Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the
-
7 months ago benzinga.com
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
-
7 months ago benzinga.com
Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40
Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.
-
7 months ago benzinga.com
Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41
Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.
7 months ago benzinga.com
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualcomm, Wells Fargo raises United Natural Foods.
7 months ago benzinga.com
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags strong launch potential.
-
7 months ago benzinga.com
Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $29 to $32.
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42
HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.
-
7 months ago benzinga.com
FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome
https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
7 months ago benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
-
8 months ago benzinga.com
BTIG Maintains Buy on Denali Therapeutics, Raises Price Target to $36
BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.
-
8 months ago benzinga.com
Denali Therapeutics Q4 EPS $(0.73) Beats $(0.76) Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 4.45 percent. This is a 8.96 percent decrease over losses of…
-
8 months ago benzinga.com
Wolfe Research Initiates Coverage On Denali Therapeutics with Peer Perform Rating
Wolfe Research analyst Rudy Li initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Peer Perform rating.
8 months ago benzinga.com
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, raising trial design concerns and pushing the approval timeline.
-
8 months ago benzinga.com
BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.
-
8 months ago benzinga.com
Denali Therapeutics Reveals Enzyme TransportVehicle Progress Across Three Clinical Programs For Treatment of Lysosomal Storage Disorders; Analysis From Continued Follow-Up Of Phase 1/2 Clinical Trial Data In Hunter Syndrome Reinforces Potential For Tividenofusp Alfa To Address Full Disease Spectrum; Preliminary Phase 1/2 Study Data Show Treatment With DNL126 Reduced Disease Biomarkers In Cerebrospinal Fluid And Peripheral Tissue
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness…
-
9 months ago benzinga.com
Denali Therapeutics Presents Data On Enzyme TransportVehicle Programs At 2026 WORLDSymposium
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase…
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
Denali Therapeutics' Tividenofusp Alfa Demonstrates Biomarker And Clinical Improvements In Hunter Syndrome, Published In NEJM As FDA Review Nears April 2026 Decision
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and…
-
10 months ago benzinga.com
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.
10 months ago benzinga.com
Cracker Barrel Posts Downbeat Q1 Results, Joins GameStop, AeroVironment And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Cracker Barrel Posts Downbeat Q1 Results, Joins GameStop, AeroVironment And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
10 months ago benzinga.com
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
Denali Therapeutics Announces $200M Proposed Offering Of Common Stock And Pre-Funded Warrants
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded…
11 months ago benzinga.com
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
-
11 months ago benzinga.com
Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $31
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $30 to $31.
-
11 months ago benzinga.com
BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.
-
11 months ago benzinga.com
Denali Therapeutics And Royalty Pharma Announce $275M Synthetic Royalty Funding Agreement Based On Future Net Sales Of Tividenofusp Alfa
Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp…
-
1 year ago benzinga.com
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.
-
2 years ago benzinga.com
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday